Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema
Podcast
Podcaster
Beschreibung
vor 14 Jahren
Background: Our purpose was to compare the effect of triamcinolone
and bevacizumab (Avastin) on the retinal thickness and functional
outcome in patients with diabetic macular edema. Methods and
Materials: A collective of 32 patients, who had been treated by a
single 4.0-mg intravitreal triamcinolone injection (group 1), was
matched to 32 patients ('matched pairs'), who had received 3
injections of 1.25 mg of bevacizumab within 3 months in 4-week
intervals (group 2). The outcome variables were changes in best
corrected visual acuity (VA) and central retinal thickness 3 months
after therapy. Results: Both groups did not differ regarding
preoperative VA and central retinal thickness measured by optical
coherence tomography. The baseline mean VA was 0.72 +/- 0.39 logMAR
in group 1 and 0.73 +/- 0.39 logMAR in group 2 (p = 0.709). The
mean central retinal thickness measured by optical coherence
tomography was 548 +/- 185 mu m in group 1 and 507 +/- 192 mu m in
group 2. While the patients in group 1 experienced a slight
increase in VA of on average 0.7 lines following a single
triamcinolone injection to a mean of 0.64 +/- 0.40 logMAR (p =
0.066) after 3 months, the patients in group 2 showed almost no
effect on VA with an average increase of 0.2 lines to a mean VA of
0.72 +/- 0.30 logMAR (p = 0.948) following 3 intravitreal
injections of bevacizumab. Comparing the effect on VA between both
groups no statistically significant difference (p = 0.115) was
noted. Concerning decrease in central retinal thickness both
therapies were highly effective (p < 0.001 each), again, without
statistically significant difference between the groups (p <
0.128). Conclusion: Our data suggest that a single triamcinolone
injection may be as effective as a 3 times repeated intravitreal
administration of bevacizumab for the treatment of diabetic macular
edema. Further prospective trials should be performed. Copyright
(C) 2010 S. Karger AG, Basel
and bevacizumab (Avastin) on the retinal thickness and functional
outcome in patients with diabetic macular edema. Methods and
Materials: A collective of 32 patients, who had been treated by a
single 4.0-mg intravitreal triamcinolone injection (group 1), was
matched to 32 patients ('matched pairs'), who had received 3
injections of 1.25 mg of bevacizumab within 3 months in 4-week
intervals (group 2). The outcome variables were changes in best
corrected visual acuity (VA) and central retinal thickness 3 months
after therapy. Results: Both groups did not differ regarding
preoperative VA and central retinal thickness measured by optical
coherence tomography. The baseline mean VA was 0.72 +/- 0.39 logMAR
in group 1 and 0.73 +/- 0.39 logMAR in group 2 (p = 0.709). The
mean central retinal thickness measured by optical coherence
tomography was 548 +/- 185 mu m in group 1 and 507 +/- 192 mu m in
group 2. While the patients in group 1 experienced a slight
increase in VA of on average 0.7 lines following a single
triamcinolone injection to a mean of 0.64 +/- 0.40 logMAR (p =
0.066) after 3 months, the patients in group 2 showed almost no
effect on VA with an average increase of 0.2 lines to a mean VA of
0.72 +/- 0.30 logMAR (p = 0.948) following 3 intravitreal
injections of bevacizumab. Comparing the effect on VA between both
groups no statistically significant difference (p = 0.115) was
noted. Concerning decrease in central retinal thickness both
therapies were highly effective (p < 0.001 each), again, without
statistically significant difference between the groups (p <
0.128). Conclusion: Our data suggest that a single triamcinolone
injection may be as effective as a 3 times repeated intravitreal
administration of bevacizumab for the treatment of diabetic macular
edema. Further prospective trials should be performed. Copyright
(C) 2010 S. Karger AG, Basel
Weitere Episoden
vor 14 Jahren
Kommentare (0)